This program aims to develop anti-TLR therapeutic monoclonal antibody for immuno-oncology.
Toll-like receptors (TLRs) have recently been identified as key factors in the pathogenesis of tumors, innate and adaptive immune cells regulation, and tumor infiltration.
TLR-mediated metabolic reprogramming is important for the activation, maturation, and immunogenic function of macrophages and DCs. Studies from a variety of preclinical animal models and clinical trials show that TLR stimulation in tumor cells mediates tumor survival and growth. Recent studies also suggest that TLRs directly regulate tumor metabolism, affecting tumor behavior and function in melanoma, prostate cancer, head, neck, and breast cancer. In addition, increasing evidence supports that TLR signaling also affects the differentiation and function of T cell subsets. In summary, TLR-based immunotherapy may show a great promise in cancer research.
TLRs, a type I membrane protein, are the best-studied pattern recognition receptors (PRRs) that consist of 10 functional members. They exist in immune cells mostly as homodimers or heterodimers. The extracellular domain of TLR protrudes out of the membrane and binds to PAMP / DAMP, while the conserved toll / IL-1 receptor (TIR) exists in the intracellular domain to coordinate the downstream signaling pathway inside cell. The cellular localization of TLR family members reflects the location of its activated PAMP / DAMP ligand: TLR1, 2, 4, 5 and 6 are localized at the plasma membrane and primarily responsive to bacterial proteins; while TLRs 3, 7, 8 and 9 are located in the endosome and reacts to the intracellular compartments of the lysosome.
Fig.1 TLRs mediated the T cells response and programmed cell death process toward tumor environment.1
Here are some published data about TLR working as a potential target for cancer immunotherapy.
Fig.2 Pam3CSK4 plus anti–CTLA-4 antibody enhances tumor rejection, increases survival, and produces immunological memory after B16/F10 tumor challenge.2
Fig.3 Treatment with 1V270 or SD-101 suppresses tumor growth of HPV-positive HNSCC.3
We have extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.
Fig.4 Project pipeline management of therapeutic monoclonal antibody.
Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop anti-TLR therapeutic monoclonal antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership. For any partners interest in our Next-IO™ programs, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.
With our quality control protocol and knowledge of global regulatory requirements, we can help our partners advance their programs with more chance to succeed. Look forward to cooperating with you in the near future.
For Research Use Only | Not For Clinical Use